% 0期刊文章%一个路易莎Imberti费德里科•Serana % %一个克劳迪奥·玛丽亚·阿马托% Gasperini %一维托里奥Martinelli安吉洛Ghezzi % %一个莱安德罗Provinciali %玛丽亚罗莎Rottoli %斯特凡诺Sotgiu %一个塞吉奥Stecchi %米歇尔·玛丽亚·维奇%一个另·卡普拉毛罗·Zaffaroni % % T IFNβ研究生物活性损失由MxA mRNA量化患者允许在多发性硬化症患者残疾的预测进展(P04.140) % D J神经病学2013% % P P04.140-P04.140 % V 80% N % X 7补充目的:确定最佳IFNβ生物活性指标用于正常的临床实践和预防多发性硬化症(MS)的进展。首页背景:巴布anti-IFNβ抗体的检测,NAb或MxA量化并不总是经常表现在临床设置,因为它的相关性与临床结果的措施仍然有争议。类似地,IFNAR子单元的作用/亚型调制IFNβ生物活性并不明确。设计/方法:MS患者天真IFNβ疗法(# 118)参与了一项多中心的纵向研究,为36个月随访6个月一次。MxA和IFNAR信使rna被实时PCR量化,芭布斯和radioimmunoprecipitation的小伙子发现了细胞病变效应抑制试验。至少1点eds的存在增加24或36个月后被认为是疾病进展的标志。统计分析是由线性混合模型和逻辑回归。结果:MxA感应受损在芭布斯的存在和小伙子,和响应IFNβ治疗非常异构,包括稳定的或暂时的,早期或晚期患者丧失IFNβ生物活性(巴布+ / NAb + / MxA -)。在这些措施的生物活性损失,只有MxA可能相关疾病恶化,因为它在6 ~ 24月,平均水平调整后复发的风险,预测的风险增加1-point-EDSS增加后24个月(每个log2MxA优势比:0.53;置信区间:0.31—-0.93)。IFNAR子单元/亚型调制没有诱导IFNβ生物活性的丧失; indeed, higher levels of the soluble isoform transcript were associated with higher MxA values.CONCLUSIONS: MxA quantification predicted a risk of disability progression likely due to IFNβ bioactivity decrease. Together with its feasibility in the routine laboratory setting, these data further warrant the quantification of MxA mRNA as the primary tool for IFNβ therapy monitoring.Supported by: Biogen Idec Italia.Disclosure: Dr. Serana has nothing to disclose. Dr. Imberti has received research support from Biogen Idec and Merck Serono. Dr. Amato has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis as a scientific advisory board member and as a speaker. Dr. Amato has received research support from Biogen Idec, Merck Serono, Bayer Schering Pharma and Sanofi Aventis. Dr. Gasperini has received personal compensation for activities with Merck Serono, Bayer Pharmaceuticals Corporation, Biogen Dompe, and Aventis as a speaker. Dr. Ghezzi has received personal compensation for activities with Merck Serono, Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Novartis, and Actelion Pharmaceu. Dr. Martinelli has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., and sanofi-aventis. Dr. Provinciali has nothing to disclose. Dr. Rottoli has nothing to disclose. Dr. Sotgiu has nothing to disclose. Dr. Stecchi has nothing to disclose. Dr. Vecchio has nothing to disclose. Dr. Zaffaroni has nothing to disclose. Dr. Capra has received personal compensation for activities with Biogen Idec, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis.Wednesday, March 20 2013, 7:30 am-12:00 pm %U